Michael Pillinger, ACR 2022: An analysis of neutrophil-to-lymphocyte ratio changes in patients with uncontrolled gout receiving pegloticase therapy
Pegloticase is a urate-lowering therapy that is approved for the treatment of gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss whether urate lowering therapy impacted the neutrophil-to-lymphocyte ratio in patients with uncontrolled gout.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials.’ (Abstract number: 1803) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What were the aims and design of your study? (0:16)
- What was the impact of urate lowering with pegloticase on NLR? (4:01)
- What has this study taught us and what further research is planned? (9:03)
Disclosures: Michael Pillinger discloses consulting for Fortress Biotech and Horizon Therapeutics and receiving grant/ research support from Hikma Pharmaceuticals and Horizon Therapeutics.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
